Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

137 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gut microbiome and immune checkpoint inhibitor toxicity.
Verheijden RJ, van Eijs MJM, Paganelli FL, Viveen MC, Rogers MRC, Top J, May AM, van de Wijgert JHHM, Suijkerbuijk KPM; UNICIT-consortium. Verheijden RJ, et al. Among authors: suijkerbuijk kpm. Eur J Cancer. 2025 Jan 4;216:115221. doi: 10.1016/j.ejca.2025.115221. Online ahead of print. Eur J Cancer. 2025. PMID: 39793444 Free article.
Deep learning on CT scans to predict checkpoint inhibitor treatment outcomes in advanced melanoma.
Ter Maat LS, De Mooij RAJ, Van Duin IAJ, Verhoeff JJC, Elias SG, Leiner T, van Amsterdam WAC, Troenokarso MF, Arntz ERAN, Van den Berkmortel FWPJ, Boers-Sonderen MJ, Boomsma MF, Van den Eertwegh FJM, de Groot JW, Hospers GAP, Piersma D, Vreugdenhil A, Westgeest HM, Kapiteijn E, De Wit AA, Blokx WAM, Van Diest PJ, De Jong PA, Pluim JPW, Suijkerbuijk KPM, Veta M. Ter Maat LS, et al. Among authors: suijkerbuijk kpm. Sci Rep. 2024 Dec 30;14(1):31668. doi: 10.1038/s41598-024-81188-2. Sci Rep. 2024. PMID: 39738216 Free PMC article.
Corrigendum to "Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry" [Eur. J. Cancer 212, 2024, 115056].
Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Bloem M, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Holtslag CE, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Portielje JEA, de Glas NA. Özkan A, et al. Among authors: suijkerbuijk kpm. Eur J Cancer. 2024 Dec 26;216:115194. doi: 10.1016/j.ejca.2024.115194. Online ahead of print. Eur J Cancer. 2024. PMID: 39732138 No abstract available.
Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
Reijers ILM, Menzies AM, Lopez-Yurda M, Versluis JM, Rozeman EA, Saw RPM, van Houdt WJ, Kapiteijn E, van der Veldt AAM, Suijkerbuijk KPM, Eriksson H, Hospers GAP, Klop WMC, Torres Acosta A, Grijpink-Ongering L, Gonzalez M, van der Wal A, Al-Mamgani A, Spillane AJ, Scolyer RA, van de Wiel BA, van Akkooi ACJ, Long GV, Blank CU. Reijers ILM, et al. Among authors: suijkerbuijk kpm. Eur J Cancer. 2025 Jan;214:115141. doi: 10.1016/j.ejca.2024.115141. Epub 2024 Nov 19. Eur J Cancer. 2025. PMID: 39602990 Clinical Trial.
Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
Amaral T, Ottaviano M, Arance A, Blank C, Chiarion-Sileni V, Donia M, Dummer R, Garbe C, Gershenwald JE, Gogas H, Guckenberger M, Haanen J, Hamid O, Hauschild A, Höller C, Lebbé C, Lee RJ, Long GV, Lorigan P, Muñoz Couselo E, Nathan P, Robert C, Romano E, Schadendorf D, Sondak V, Suijkerbuijk KPM, van Akkooi ACJ, Michelin O, Ascierto PA; ESMO Guidelines Committee. Electronic address: [email protected]. Amaral T, et al. Among authors: suijkerbuijk kpm. Ann Oncol. 2025 Jan;36(1):10-30. doi: 10.1016/j.annonc.2024.11.006. Epub 2024 Nov 14. Ann Oncol. 2025. PMID: 39550033 No abstract available.
Validation of 11 added items of the outpatient version of the Utrecht Symptom Diary in patients receiving chemotherapy or targeted therapy.
Koldenhof JJ, Akpobome BO, Zweers D, Klaasse S, Teunissen SCCM, Witteveen PO, Suijkerbuijk KPM, de Graeff A, van der Baan FH. Koldenhof JJ, et al. Among authors: suijkerbuijk kpm. J Patient Rep Outcomes. 2024 Oct 18;8(1):120. doi: 10.1186/s41687-024-00794-w. J Patient Rep Outcomes. 2024. PMID: 39422800 Free PMC article.
Adjuvant immunotherapy in older patients with stage III and resected stage IV melanoma: Toxicity and recurrence-free survival outcomes from the Dutch melanoma treatment registry.
Özkan A, Kapiteijn E, van den Bos F, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Bloem M, Blokx WAM, Boers-Sonderen MJ, Bonenkamp JJ, van den Eertwegh AJM, de Groot JWB, Haanen JB, Holtslag CE, Hospers GAP, Piersma D, van Rijn RS, Stevense-den Boer AM, Suijkerbuijk KPM, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Portielje JEA, de Glas NA. Özkan A, et al. Among authors: suijkerbuijk kpm. Eur J Cancer. 2024 Nov;212:115056. doi: 10.1016/j.ejca.2024.115056. Epub 2024 Sep 30. Eur J Cancer. 2024. PMID: 39368226 Free article.
Long-Term Survival in Patients With Advanced Melanoma.
van Not OJ, van den Eertwegh AJM, Jalving H, Bloem M, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot J W B JW, Hospers GAP, Kapiteijn E, Leeneman B, D P, Stevense-den Boer M, van der Veldt AAM, Vreugdenhil G G, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: suijkerbuijk kpm. JAMA Netw Open. 2024 Aug 1;7(8):e2426641. doi: 10.1001/jamanetworkopen.2024.26641. JAMA Netw Open. 2024. PMID: 39141388 Free PMC article.
137 results